Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study data
Year: 2026
Type: article
Abstract: This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.
Source: Medical alphabet
Institutions: Moscow Clinical Scientific Center, Pirogov Russian National Research Medical University, Russian Cancer Research Center NN Blokhin, Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky, Ministry of Health of the Russian Federation, Tyumen Regional Oncological Dispensary, Republican Oncological Clinical Dispensary, Moscow City Oncology Hospital №62, Krasnoyarsk State Medical University, Novartis (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: hormone receptor-positive HER2-negative breast cancer, ribociclib, endocrine therapy, combination chemotherapy, first-line therapy, patient selection, ECOG performance status, estrogen receptor expression, progesterone receptor expression, metastatic breast cancer, real-world clinical practice, Russia
Open Access status: hybrid
OpenAlex ID: W7235857351
